

Table of contents

List of Contributors xi

Preface xiii

1 An Introduction to Pathology Techniques 1

Elizabeth McInnes

1.1 Animal Considerations 2

1.2 Necropsy 2

1.3 Lung Inflation with Fixative 5

1.4 Fixation 5

1.5 Making Glass Slides 6

1.5.1 Trimming 6

1.5.2 Tissue Processing 9

1.5.3 Embedding 9

1.5.4 Microtoming 9

1.5.5 Staining 9

1.5.6 Quality Control 11

1.6 Special Histochemical Stains 12

1.7 Decalcification 13

1.8 Immunohistochemistry 13

1.9 Tissue Crossreactivity Studies 15

1.10 Electron Microscopy 15

1.11 In Situ Hybridisation 16

1.12 Laser Capture Microscopy 16

1.13 Confocal Microscopy 16

1.14 Image Analysis	17
1.15 Digital Imaging	17
1.16 Spermatoocyte Analysis	17
1.17 Good Laboratory Practice	17
1.18 Inhalation Studies	18
1.19 Continuous•]Infusion Studies	18
1.20 Carcinogenicity	19
1.21 Biologicals	19
1.22 The Pathology Report	20
1.23 Conclusion	20
References	20

2 Recording Pathology Data 23

Cheryl L. Scudamore

2.1 What is a Pathology Finding?	24
2.2 Standardisation of Pathology Findings	24
2.2.1 Semiquantitative Analysis	24
2.2.2 Nomenclature/Controlled Terminology	26
2.2.3 Ontological Approach	28
2.3 ‘Inconsistencies’ in Pathology Recording	28
2.3.1 Diagnostic Drift	28
2.3.2 Thresholds	28
2.3.3 Lumping versus Splitting	29
2.4 Blind Review	30
2.5 Historical Control Data: Pros and Cons	30

2.6 The Use of Peer Review in Pathology 32

References 32

3 General Pathology and the Terminology of Basic Pathology 35

Elizabeth McInnes

3.1 Cellular Responses to Insults 35

3.2 Inflammation 41

3.3 Circulatory Disturbances 46

3.4 Disorders of Tissue Growth 52

3.5 Tissue Repair and Healing 53

3.6 Neoplasia 54

3.7 Immune System 55

References 57

4 Common Spontaneous and Background Lesions in Laboratory Animals 59

Elizabeth McInnes

4.1 Rats 62

4.2 Mice 63

4.3 Dogs 66

4.4 Minipigs 66

4.5 Non•]Human Primates 67

4.6 Rabbits 67

4.7 Experimental Procedures 67

4.8 Causes of Death in Rats and Mice 67

4.9 Conclusion 68

References 69

5 Target Organ Pathology 72

Elizabeth McInnes

5.1 Skin 72

5.2 Eye 76

5.3 Gastrointestinal Tract 78

5.4 Liver 83

5.5 Respiratory System 85

5.6 Urinary System 89

5.7 Lymphoreticular System 94

5.8 Musculoskeletal System 95

5.9 Cardiovascular System 97

5.10 Endocrine System 99

5.11 Reproductive System 102

5.12 Central and Peripheral Nervous System 104

5.13 Ear 106

References 106

6 Clinical Pathology 112

Barbara von Beust

6.1 Clinical Pathology in Study Phases and Good Laboratory Practice 112

6.1.1 Preanalytic Phase: Study Plan 113

6.1.2 Analytic Phase: Data Generation 114

6.1.3 Postanalytic Phase: Data Interpretation and Reporting 114

6.1.4 Good Laboratory Practice 114

6.2 What is Measured in Clinical Pathology? 115

6.2.1 Interference by Haemolysis, Lipaemia and Icterus	116
6.3 Haematology	117
6.3.1 Manual and Automated Techniques in Haematology	118
6.3.2 Haematocrit and Red Blood Cell Mass	119
6.3.3 Blood Cells	120
6.3.4 The Standard Haematology Profile	124
6.3.5 Bone Marrow	125
6.4 Coagulation	125
6.4.1 Standard Coagulation Profile	126
6.4.2 Prothrombin Time	127
6.4.3 Activated Partial Thromboplastin Time	127
6.4.4 Fibrinogen	127
6.5 Clinical Chemistry	127
6.5.1 Metabolites	127
6.5.2 Enzymes	129
6.5.3 Electrolytes and Minerals	129
6.5.4 Standard Chemistry Profiles	130
6.6 Urinalysis	131
6.7 Acute• JPhase Proteins	131
6.8 The Biomarker Concept	132
6.9 Reference Intervals	133
6.10 Instrumentation, Validation and Quality Control	133
6.11 Data Analysis and Interpretation	134

6.12 Reporting	135
6.13 Food Consumption and Body Weight (Gain)	136
6.14 Organ Weights	136
6.15 Examples of Typical Clinical Pathology Profile Changes in Toxicologic Clinical Pathology	136
6.15.1 Reduced Red Blood Cell Mass due to Chronic Disease	138
6.15.2 Stress Response	139
6.15.3 Reduced Red Blood Cell Mass due to Excessive Blood Sampling	139
6.15.4 Common Artefacts	139
6.16 Microsampling	140
6.17 Conclusion	141
Acknowledgments	141
References	141
7 Adversity: A Pathologist's Perspective	145
<i>Bhanu Singh</i>	
7.1 LOAEL, NOEL and NOAEL: Definition	146
7.2 Adversity	147
7.3 Determining Adversity using Pathology Findings: Factors to Consider	149
7.3.1 Severity	149
7.3.2 Functional Effect	150
7.3.3 Primary versus Secondary Effects	151
7.3.4 Physiological Adaptability	152
7.3.5 Reversibility of the Lesion	152
7.3.6 Pharmacological Effect	153

7.4 Communicating NOAEL in Toxicity Studies 153

7.5 Conclusion 154

References 154

8 Limitations of Pathology and Animal Models 157

Natasha Neef

8.1 Limitations of In Vivo Animal Models 157

8.1.1 Traditional Laboratory Species Used as General Toxicology Models 157

8.1.2 The Test Article May Not have Sufficient Pharmacological Activity in Routine Toxicology Species 158

8.1.3 The Model May Not Identify Hazards Related to Causation or Exacerbation of Pathology that is Unique to Humans or Undetectable in Animals 159

8.1.4 The Model May Not Identify Hazards with Low Incidence/Low Severity 159

8.1.5 Potential for Misinterpretation of Reversibility/Recovery for Low•]Incidence Findings 160

8.1.6 Potential for Over•] or Underestimation of the Relationship to Test Article of Findings that have High Spontaneous Incidence in Laboratory Species, but are Relatively Rare in Humans 160

8.1.7 Exclusive Use of Young, Healthy Animals Kept in Ideal Conditions Gives Limited Predictivity for Aged/Diseased Human Populations 161

8.2 Efficacy/Disease Models as Toxicology Models 162

8.3 Limitations of Efficacy/Disease Models as Toxicology Models 164

8.3.1 Lack of Validation as Safety/Toxicology Models 164

8.3.2 Disease Models Rarely Have All the Elements of the Equivalent Human Disease 165

8.3.3 Limited Sensitivity Produced by Increased Interanimal Variability amongst Diseased Animals and/or Low Animal Numbers 165

8.3.4 Lack of Historical Data	166
8.3.5 Risk Associated with Nonregulated Laboratory Conditions	166
8.4 Limitations of Pathology within In Vivo Toxicology Models	167
8.4.1 Anatomic Pathology Evaluation Will Not Identify Hazards with No Morphological Correlates	167
8.4.2 Limitations of Pathology when Evaluating Moribund Animals or Animals Found Dead on Study	168
8.4.3 Limitations of Anatomic and/or Clinical Pathology End Points within other Types of In Vivo Preclinical Safety Study	168
8.4.4 Limitations of Histopathology Related to Sampling Error	169
8.4.5 Limitations of Quantitative Anatomic Pathology	170
8.4.6 Limitations of Pathology Related to Subjectivity and Pathologist Error	173
8.4.7 Anatomic Pathology Error/Missed Findings	173
8.4.8 Subjectivity and Pathologist Variability	175
8.5 Managing Risk Associated with Subjectivity and the Potential for Pathologist Error	176
8.5.1 Choice of Study Pathologist	176
8.5.2 Peer Review	176
8.5.3 Review of the Anatomic Pathology Data	177
8.5.4 Review of Anatomic Pathology Data Interpretation	177
References	179
Glossary	184
Index	187